Mechanisms of acquired resistance to osimertinib in EGFR T790M-Positive lung adenocarcinoma
Kefan Cui, Renjie Zhu, Jingmeng Li · 2026
Read Mechanisms of acquired resistance to osimertinib in EGFR T790M-Positive lung adenocarcinoma by Kefan Cui, Renjie Zhu, Jingmeng Li (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13585410.txt.
Description
Kefan Cui, Renjie Zhu, and Jingmeng Li chart, in 2026 work, how lung cancer learns to beat a key targeted drug. The drug is the standard for patients whose tumours carry a set gene change, but the cancer finds ways around it in time. Knowing those ways guides what care comes next, so the team read records from eighty-six patients whose disease grew on the drug.
Gene tests after that point found a spread of escape routes. A fresh change in the target gene led, with side paths through other growth genes next. In about a fourth, more than one route ran at once. Some tumours changed type outright, and those patients fared worst. Lab cell tests backed one side path's role. The team stresses how mixed the picture is.
Catalog record
| CREATOR | Kefan Cui, Renjie Zhu, Jingmeng Li |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 56 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |